Pharma News

This is the best time to invest in Pharma & Medical device sector in India, as per Shri  DV Sadananda Gowda. Pharma sector  is likely to grow in to 65-billion-dollar industry by 2024 and to 120 billion dollars by 2030 and Medical Devices industry to reach US $50 Billion by 2025.

Caption : A Purdue University team has developed a novel testing platform to evaluate how breast cancer cells respond to the recurrent stretching that occurs in the lungs during breathing.

Caption: Abnormal neurofibrillary tangles (NFTs) -- a buildup of tau protein in parts of the brain -- helped Edward Lee, MD, PhD, an assistant professor of Pathology and Laboratory Medicine, and other Penn Medicine scientists uncover this new form of dementia.

The Covid-19 pandemic has brought the spotlight on the health-promotive and disease-preventive solutions of Ayush disciplines. What has not come into the limelight is the emerging nation-wide trend in the Ayush disciplines, of taking up evidence-based studies.

Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ® (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight. This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.

Vaccine Innovator, Bharat Biotech announces today, a licensing agreement with Washington University School of Medicine in St. Louis for a novel chimp- adenovirus, single dose intranasal vaccine for COVID-19. Bharat Biotech owns the rights to distribute the vaccine in all markets except USA, Japan and Europe.